Fagron NV (FRA:4A5)

Market Cap	1.62B +22.9%
Revenue (ttm)	918.75M +11.9%
Net Income	85.69M +9.9%
EPS	1.17 +9.6%
Shares Out	n/a
PE Ratio	18.93
Forward PE	16.01
Dividend	0.25 (1.08%)
Ex-Dividend Date	May 19, 2025

Volume	n/a
Average Volume	n/a
Open	23.10
Previous Close	22.85
Day's Range	23.10 - 23.10
52-Week Range	17.74 - 23.10
Beta	n/a
RSI	55.65
Earnings Date	Feb 12, 2026

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointest...

• Industry: Medical, Dental, and Hospital Equipment and Supplies
• Founded: 1990
• Employees: 3,989
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4A5

Financial Performance

In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.